US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist
  • 410.650
  • +2.470+0.61%
Close Dec 26 16:00 ET
105.75BMarket Cap-216.13P/E (TTM)

Vertex Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
11.61%2.77B
6.11%2.65B
13.30%2.69B
10.51%9.87B
9.34%2.52B
6.39%2.48B
13.52%2.49B
13.22%2.37B
17.91%8.93B
11.10%2.3B
Operating revenue
11.61%2.77B
6.11%2.65B
13.30%2.69B
10.51%9.87B
9.34%2.52B
6.39%2.48B
13.52%2.49B
13.22%2.37B
17.92%8.93B
11.10%2.3B
Cost of revenue
23.19%392.6M
20.51%371.9M
28.36%342.6M
16.84%1.26B
29.90%368M
10.12%318.7M
17.88%308.6M
8.58%266.9M
19.48%1.08B
14.51%283.3M
Gross profit
9.91%2.38B
4.08%2.27B
11.39%2.35B
9.64%8.61B
6.45%2.15B
5.86%2.16B
12.93%2.18B
13.84%2.11B
17.69%7.85B
10.64%2.02B
Operating expense
16.19%1.25B
27.71%1.34B
15.06%1.13B
34.05%4.83B
59.78%1.72B
20.41%1.07B
28.56%1.05B
20.51%983.7M
-7.47%3.6B
13.43%1.08B
Selling and administrative expenses
40.94%371.8M
41.74%372.2M
42.14%342.7M
20.31%1.14B
38.03%369.1M
6.89%263.8M
21.97%262.6M
12.04%241.1M
12.45%944.7M
4.78%267.4M
Research and development costs
8.14%875.9M
23.02%966.6M
6.26%789.1M
38.94%3.69B
66.96%1.35B
25.58%810M
30.93%785.7M
23.54%742.6M
-12.96%2.66B
16.61%809.6M
Operating profit
3.72%1.13B
-17.72%934.9M
8.18%1.22B
-11.05%3.78B
-54.49%428.9M
-5.39%1.09B
1.55%1.14B
8.58%1.12B
52.93%4.25B
7.62%942.4M
Net non-operating interest income expense
-20.57%124.7M
9.81%146.6M
53.60%170.8M
535.41%570.6M
127.02%168.9M
383.08%157M
3,613.16%133.5M
936.09%111.2M
258.66%89.8M
635.25%74.4M
Non-operating interest income
-21.26%132.2M
8.15%156.5M
47.80%181.2M
325.10%614.7M
108.72%179.5M
263.42%167.9M
1,239.81%144.7M
7,562.50%122.6M
2,851.02%144.6M
7,066.67%86M
Non-operating interest expense
-31.19%7.5M
-11.61%9.9M
-8.77%10.4M
-19.53%44.1M
-8.62%10.6M
-20.44%10.9M
-23.29%11.2M
-23.49%11.4M
-10.89%54.8M
-23.18%11.6M
Other net income (expense)
53.20%-32.2M
-4,029.92%-4.47B
68.62%-107.9M
126.84%28.8M
816.33%549.8M
-647.83%-68.8M
-19.27%-108.3M
-411.00%-343.9M
-1,441.25%-107.3M
559.34%60M
Special income (charges)
71.08%-15.3M
-3,948.77%-4.45B
77.78%-76.7M
-10.26%51.6M
514.27%559.6M
-100.38%-52.9M
-765.35%-109.9M
-6,376.36%-345.2M
1,754.84%57.5M
4,455.00%91.1M
-Less：Restructuring and merger&acquisition
-75.00%300K
183.33%500K
94.74%-100K
10.26%-51.6M
-2,894.44%-50.3M
146.15%1.2M
98.78%-600K
74.67%-1.9M
-1,754.84%-57.5M
190.00%1.8M
-Less:Other special charges
-70.99%15M
3,926.33%4.45B
-77.87%76.8M
----
----
78.28%51.7M
78.51%110.5M
17,255.00%347.1M
----
----
Other non- operating income (expenses)
-6.29%-16.9M
-1,543.75%-23.1M
-2,500.00%-31.2M
86.17%-22.8M
68.49%-9.8M
-192.44%-15.9M
102.05%1.6M
101.79%1.3M
-3,463.27%-164.8M
-538.03%-31.1M
Income before tax
3.81%1.22B
-391.97%-3.39B
43.48%1.28B
3.48%4.38B
6.58%1.15B
0.24%1.18B
13.38%1.16B
-6.63%891.5M
55.01%4.23B
23.64%1.08B
Income tax
24.18%178.7M
-17.66%202.4M
-6.36%179.5M
-16.50%760.2M
-30.67%178.8M
-41.48%143.9M
14.91%245.8M
-0.52%191.7M
134.46%910.4M
155.85%257.9M
Net income
0.98%1.05B
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
Net income continuous Operations
0.98%1.05B
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
Minority interest income
Net income attributable to the parent company
0.98%1.05B
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
0.98%1.05B
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
Basic earnings per share
1.00%4.05
-492.11%-13.92
56.62%4.26
8.33%14.05
17.87%3.76
10.47%4.01
11.99%3.55
-9.03%2.72
42.68%12.97
5.63%3.19
Diluted earnings per share
1.01%4.01
-495.45%-13.92
56.51%4.21
8.35%13.89
17.78%3.71
10.58%3.97
12.46%3.52
-9.12%2.69
42.29%12.82
5.00%3.15
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 11.61%2.77B6.11%2.65B13.30%2.69B10.51%9.87B9.34%2.52B6.39%2.48B13.52%2.49B13.22%2.37B17.91%8.93B11.10%2.3B
Operating revenue 11.61%2.77B6.11%2.65B13.30%2.69B10.51%9.87B9.34%2.52B6.39%2.48B13.52%2.49B13.22%2.37B17.92%8.93B11.10%2.3B
Cost of revenue 23.19%392.6M20.51%371.9M28.36%342.6M16.84%1.26B29.90%368M10.12%318.7M17.88%308.6M8.58%266.9M19.48%1.08B14.51%283.3M
Gross profit 9.91%2.38B4.08%2.27B11.39%2.35B9.64%8.61B6.45%2.15B5.86%2.16B12.93%2.18B13.84%2.11B17.69%7.85B10.64%2.02B
Operating expense 16.19%1.25B27.71%1.34B15.06%1.13B34.05%4.83B59.78%1.72B20.41%1.07B28.56%1.05B20.51%983.7M-7.47%3.6B13.43%1.08B
Selling and administrative expenses 40.94%371.8M41.74%372.2M42.14%342.7M20.31%1.14B38.03%369.1M6.89%263.8M21.97%262.6M12.04%241.1M12.45%944.7M4.78%267.4M
Research and development costs 8.14%875.9M23.02%966.6M6.26%789.1M38.94%3.69B66.96%1.35B25.58%810M30.93%785.7M23.54%742.6M-12.96%2.66B16.61%809.6M
Operating profit 3.72%1.13B-17.72%934.9M8.18%1.22B-11.05%3.78B-54.49%428.9M-5.39%1.09B1.55%1.14B8.58%1.12B52.93%4.25B7.62%942.4M
Net non-operating interest income expense -20.57%124.7M9.81%146.6M53.60%170.8M535.41%570.6M127.02%168.9M383.08%157M3,613.16%133.5M936.09%111.2M258.66%89.8M635.25%74.4M
Non-operating interest income -21.26%132.2M8.15%156.5M47.80%181.2M325.10%614.7M108.72%179.5M263.42%167.9M1,239.81%144.7M7,562.50%122.6M2,851.02%144.6M7,066.67%86M
Non-operating interest expense -31.19%7.5M-11.61%9.9M-8.77%10.4M-19.53%44.1M-8.62%10.6M-20.44%10.9M-23.29%11.2M-23.49%11.4M-10.89%54.8M-23.18%11.6M
Other net income (expense) 53.20%-32.2M-4,029.92%-4.47B68.62%-107.9M126.84%28.8M816.33%549.8M-647.83%-68.8M-19.27%-108.3M-411.00%-343.9M-1,441.25%-107.3M559.34%60M
Special income (charges) 71.08%-15.3M-3,948.77%-4.45B77.78%-76.7M-10.26%51.6M514.27%559.6M-100.38%-52.9M-765.35%-109.9M-6,376.36%-345.2M1,754.84%57.5M4,455.00%91.1M
-Less：Restructuring and merger&acquisition -75.00%300K183.33%500K94.74%-100K10.26%-51.6M-2,894.44%-50.3M146.15%1.2M98.78%-600K74.67%-1.9M-1,754.84%-57.5M190.00%1.8M
-Less:Other special charges -70.99%15M3,926.33%4.45B-77.87%76.8M--------78.28%51.7M78.51%110.5M17,255.00%347.1M--------
Other non- operating income (expenses) -6.29%-16.9M-1,543.75%-23.1M-2,500.00%-31.2M86.17%-22.8M68.49%-9.8M-192.44%-15.9M102.05%1.6M101.79%1.3M-3,463.27%-164.8M-538.03%-31.1M
Income before tax 3.81%1.22B-391.97%-3.39B43.48%1.28B3.48%4.38B6.58%1.15B0.24%1.18B13.38%1.16B-6.63%891.5M55.01%4.23B23.64%1.08B
Income tax 24.18%178.7M-17.66%202.4M-6.36%179.5M-16.50%760.2M-30.67%178.8M-41.48%143.9M14.91%245.8M-0.52%191.7M134.46%910.4M155.85%257.9M
Net income 0.98%1.05B-492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M
Net income continuous Operations 0.98%1.05B-492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M
Minority interest income
Net income attributable to the parent company 0.98%1.05B-492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 0.98%1.05B-492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M
Basic earnings per share 1.00%4.05-492.11%-13.9256.62%4.268.33%14.0517.87%3.7610.47%4.0111.99%3.55-9.03%2.7242.68%12.975.63%3.19
Diluted earnings per share 1.01%4.01-495.45%-13.9256.51%4.218.35%13.8917.78%3.7110.58%3.9712.46%3.52-9.12%2.6942.29%12.825.00%3.15
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Gene Editing
Gene Editing
Intraday+0.36%